Momenta, Sandoz win temporary restraining order in enoxaparin clash
This article was originally published in Scrip
Executive Summary
A US district court granted a request by Momenta Pharmaceuticals and Novartis unit Sandoz for a temporary restraining order preventing Watson Pharmaceuticals and Amphastar Pharmaceuticals from marketing or selling enoxaparin sodium injection, a generic equivalent of Paris-based Sanofi's Lovenox, in the firms' ongoing patent infringement suit (scripintelligence, 4 October 2011).